

Alaska Medical Assistance DUR Committee Meeting Minutes

Friday, January 20th, 2023

Meeting was held telephonically due to COVID-19. 1:00 PM

Drug Utilization Review Committee Attendees

Members Present	Non-Members Present
Charles Semling, PharmD (DHSS)	Umang Patel, PharmD (Magellan)
Matt Parrott, PharmD (DHSS)	Ryan Ruggles, PharmD, MSHI (Magellan)
Charles Ryan, MD	
Keri McCutcheon, RPh	
Robert Carlson, MD	
Valarie Bixler, PharmD	Members Absent
Casey Gokey, MD	Matthew Begay-Bruno, PharmD

Call to order at 1:01 PM.

Charles Semling called the meeting to order and welcomed the committee and specifically the two new members, Valarie Bixler and Casey Gokey. He then introduced Matt Parrott as the meeting coordinator.

Review of minutes from November 2022

Matt Parrott reviewed the minutes.

Charles Ryan Moved to accept the minutes.

Keri McCutcheon seconded.

There was no opposition.

Review of Agenda

Matt Parrott went over the agenda for the committee members.

Overview of Medicaid Prescription and Cost Trends

Program tend was presented to the committee. It was noted that each column was in line with the others. There is a slight uptrend in cost. The 60 and 90 day refills causes topside and bottom side around the trendline bouncing.

Top 25 reports were shown to the committee. It was noticed that Ozempic was being used more frequently, and there was some use in patients with no other evidence of having diabetes, and by statute AK Medicaid should not be paying for medications for weight loss. However due to effectiveness the state is considering altering that statute. The pharmacy reimbursement and net-net top 25 were shown to the committee. The tables are consistent with previous trends.

Change of utilization by market basket was shown to the committee. It was noted that incretin mimetics have had a 48% increase in volume.

Prospective Drug Utilization Review/Clinical Topic Areas

New Prescription Medications (Interim PA List – 6 month review)

New items proposed for the interim PA list was presented to the committee. Some of the items on this list will be reviewed both today and in the near future.

No committee opposition.

New Prior Authorizations, Quantity Limits, Edits

Upravi criteria was presented to the committee.

Keri McCutcheon moved to approve.

Charles Ryan seconded.

No committee opposition.

Cholbam criteria was presented to the committee.

Charles Ryan moved to approve.

Keri McCutcheon seconded.

No committee opposition.

Opsumit criteria was presented to the committee.

Keri McCutcheon moved to approve.

Charles Ryan seconded.

No committee opposition.

Tzield criteria was presented to the committee.

Charles Ryan moved to approve with one clerical correction.

Keri McCutcheon seconded.

No committee opposition.

Leqembi criteria was presented to the committee. Charles Semling commented that since this criteria fell under miscellaneous items for dur discussion and that it would be posted for not less than 30 days for comments prior to becoming effective. Robert Carlson commented that the approval of Leqembi was approved via the FDA Commissioner group and not by an expert panel of physicians. The committee expressed concern that it felt difficult to agree on criteria due to it not being reviewed by an expert panel. Charles Semling commented that since it is covered medication and to ensure proper use Medicaid has to have criteria and that the criteria is from the package insert. Discussion that approving criteria is better than not having criteria for a medication like this. The committee decided to accept the criteria as opposed to approve it.

Charles Semling commented that the criteria allows state review prior to the drug being administered.
Charles Ryan moved to accept the criteria.
Keri McCutcheon seconded.
No committee opposition.

Updated Entyvio criteria was presented to the committee.
Keri McCutcheon moved to approve the update.
Robert Carlson seconded.
No committee opposition.

Updated Sympazan criteria was presented to the committee.
Charles Ryan moved to accept the modified criteria.
Casey Gokey seconded.
No committee opposition.

Opioid Utilization

Opioid tables were reviewed with the committee. Members on opioids is trending down. The members are utilizing fewer combos with benzodiazepines. The members are seeing fewer providers and utilizing closer to a single pharmacy. Top 20 utilized opioids were shared with the committee. This list has not changed very much. Comparison of average MME for cancer and non-cancer patients were presented. MME per days of supply each year was presented to the committee. The trend demonstrates a decrease over time. MME level categorized by cancer patient or other was shown to the committee to show the differences in MME levels. MME per days of supply chart since 2003 was shown to the committee and it shows a steady decrease in MME. ICD-10 compliance for opioids and stimulants were presented to the committee. And there has been an increase in compliance in the opioid medications.

FDA Label Changes/FAERS Reports

FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia was discussed.

FDA Adverse Event Reporting System July-September 2022 was discussed.

Psychotropic Use in Pediatric Patients

Children in less than 6 years of age utilizing psychotropic medications was presented to the committee. Patients with more than 3 psychotropic patients over the last 12 months was presented to the committee. Patients under 21 years of age with multiple atypical antipsychotics were presented to the committee. The different charts were then compared to OCS patient population.

End of Public Meeting

Adjournment 2:10 p.m.

Next meeting date April 21st, 2023.